Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
Summary
- Eligibility
- for people ages 10-65 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated
- ID
- NCT05312879
- Phase
- Phase 2/3 Kidney Disease Research Study
- Study Type
- Interventional
- Participants
- Expecting 466 study participants
- Last Updated